[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Herlev and Gentofte Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":617},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,54,84,114,145,175,200,228,260,309,341,363,398,423,447,467,490,511,534,561,591],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100053868","halo-trial-high-medium-and-low-intensity-psychotherapy-for-binge-eating-disorder-100053868",false,"NCT07698132","HALO-TRIAL: High, Medium And LOw Intensity Psychotherapy for Binge Eating Disorder","HALO","Inclusion Criteria:\n\n* Binge Eating Disorder according to DSM-5 criteria\n* 18-65 years of age\n* Fluent Danish speaker\n\nExclusion Criteria:\n\n* Concurrent psychotherapeutic treatment\n* Use of weight loss medications within the last month (i.e., GLP-1 receptor antagonists)\n* Suicidal ideation or suicidality\n* Psychosis or psychotic disorders\n* Mania or bipolar disorder\n* Drug misuse disorder\n* Alcohol misuse disorder\n* Cluster B personality disorders in the severe range (diagnosed)\n* Dosage of Antidepressants, Antipsychotics and Stimulants must be stable for at least 6 months","ALL","18 Years","65 Years",{"count":20,"type":21},256,"ESTIMATED","INTERVENTIONAL",[24],"NA","The HALO trial is designed as a four-armed, assessor-blinded, fidelity-monitored randomized clinical trial. The goal of this randomized controlled study is to investigate the effectiveness of four different psychotherapy programs and to determine which one is most effective in reducing the number of binge-eating episodes in people with the eating disorder Binge Eating Disorder (BED), by directly comparing three intensities of Cognitive Behavioral Therapy-Enhanced against a manualized treatment as usual.\n\nParticipants will be asked to complete a 21-weeks randomized intervention and participate in follow up assesments.",[27,28,29,30,31,32,33,34,35],"Binge Eating Disorder","Binge Eating Episodes","Binge Eating\u002FLoss of Control Eating","Binge Eating Disorders","Binge Eating","Binge Eating Behaviour","Binge Eating Disorder Associated With Obesity","Eating Disorder Binge","Eating Disorders",[27,35,37,38,39,40],"Cognitive Behavioral Therapy","Psychotherapy","Randomized Controlled Trial","Evidence-based Psychiatry","RECRUITING","2026-07-07",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":45},"2024-06-10",{"date":49,"type":21},"2032-12",{"name":51,"class":52},"Herlev and Gentofte Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":53},"100563611","evaluating-the-impact-of-home-based-sleep-apnea-diagnostic-on-well-being-health-behavior-and-af-load-in-patients-with-atrial-fibrillation-using-a-decentralized-platform-100563611","NCT06618417","Evaluating the Impact of Home-Based Sleep Apnea Diagnostic on Well-Being, Health Behavior, and AF Load in Patients With Atrial Fibrillation Using a Decentralized Platform","National Decentral\u002FVirtual Randomized Trial Testing Remote Sleep Apnea Evaluation in Patients With Atrial Fibrillation","VIR-SAAF","Inclusion Criteria:\n\n* Established paroxysmal or persistent AF diagnosis\n* Owning a compatible smartphone\n* 18 years or older\n\nExclusion Criteria:\n\n* Previous investigation for sleep-disturbed breathing\n* Advanced heart failure (left ventricular dysfunction and NYHA III\u002FIV)\n* Occupational driver licenses\n* Pregnancy\n* Doxazosin or Terazosin treatment (alpha-adrenergic antagonists)\n* Peripheral arterial disease with daily intermittent claudication",{"count":63,"type":21},936,[24],"The goal of this clinical trial is to find out if testing for sleep apnea (a condition where breathing stops and starts during sleep) at home can improve well-being in people with atrial fibrillation (an irregular heartbeat condition). About 936 participants will be involved. They will either be tested for sleep apnea and treated, if needed, or not tested at all.\n\nResearchers will compare the well-being and heart-related symptoms of participants who are tested for sleep apnea to those who are not. These will be tracked using a mobile app to monitor symptoms, physical activity, and heart rhythm.\n\nMain hypothesis: Participants with atrial fibrillation who are tested and possibly treated for sleep apnea will have improved quality of life scores (measured by the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire) by at least 5 points after 18 weeks.",[67,68],"Atrial Fibrillation (AF)","Sleep Apnea",[70,71,72,73,74,75],"atrial fibrillation","decentralized","sleep apnea home-evaluation","randomized","digital health","quality of life","2026-06-09",{"date":78,"type":45},"2026-06-10",{"date":80,"type":45},"2024-12-05",{"date":82,"type":21},"2027-06-30",{"name":51,"class":52},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":53},"100639916","non-invasive-malignancy-classifiers-using-blood-biomarkers-for-lung-nodule-evaluation-100639916","NCT07623473","Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation","NIMBLE | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation","NIMBLE","Inclusion Criteria:\n\n* Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit\n* Having signed informed consent\n\nExclusion Criteria:\n\n* Active cancer, excluding non-melanoma skin cancer\n* Comorbidities that exclude the patient from clinical follow-up and final diagnosis",true,{"count":94,"type":21},1800,"OBSERVATIONAL","The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.\n\nEach blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.",[98,99],"Lung Cancer (Diagnosis)","Nodule, Solitary Pulmonary",[101,102,103,104,105],"Biomarkers","Lung nodule","Fragmentomics","Methylome","Cell-free DNA","2026-05-29",{"date":108,"type":45},"2026-06-03",{"date":110,"type":45},"2024-05-22",{"date":112,"type":21},"2028-02-01",{"name":51,"class":52},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":92,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":123,"conditions":124,"keywords":130,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":53},"100636691","a-tool-of-the-future-for-strengthening-compassion-in-a-danish-hospital-setting-100636691","NCT07568977","A Tool of the Future for Strengthening Compassion in a Danish Hospital Setting.","A Tool of the Future for Strengthening Compassion in a Danish Hospital Setting","Patients:\n\nInclusion Criteria:\n\n1. A patient at either the a. Department of Nephrology, b. Department of Internal Medicine, c. Emergency Department (ED) d. Department of Orthopedic Surgery.Rheumatology and Orthopedics or e. Perioperative and Intensive Care Department\n2. Age 18-100+\n3. All genders\n4. Danish speaking\n5. Must have had contact with at least one healthcare professional before completing the questionnaire.\n\nExclusion Criteria:\n\n1. Patient exclusion criteria:\n2. Age 0-17\n3. Non-Danish speaking\n4. Not a patient at the a. Department of Nephrology, b. Department of Internal Medicine, c. Emergency Department (ED) d. Department of Orthopedic Surgery or e. Department of Anesthesia, Operation and Intensive Care)\n5. No contact with a healthcare professional\n6. Has answered the questionnaire before\n\nHealthcare professionals:\n\nHCP inclusion criteria\n\n1. Employed in one of the five departments included (phase 1b and 2): a. Department of Nephrology, b. Department of Internal Medicine c. Emergency Department, d. Department of Orthopedic Surgery or e. Department of Anesthesia, Operation and Intensive Care.\n2. All genders\n3. Danish speaking\n4. Must have engaged with a patient\n\nHCP exclusion criteria\n\n1. Not employed in one of the five departments included (a. Department of Nephrology, b. Department of Internal Medicine, c. Emergency Department, d. Department of Orthopedic Surgery or e. Department of Anesthesia, Operation and Intensive Care)\n2. Not Danish speaking",{"count":122,"type":21},2200,"This study is a multi-phase, mixed-methods clinical investigation designed to examine the feasibility, validity, and organizational applicability of a structured measurement framework for assessing compassion in a Danish hospital setting. The study is conducted at Herlev and Gentofte Hospital and involves both patients and healthcare professionals across multiple clinical departments.\n\nThe study is structured in three sequential phases, each addressing distinct methodological and implementation components.\n\nPhase 1 (Translation and Cultural Adaptation):\n\nThe initial phase involves the linguistic translation and cultural adaptation of three versions of the Sinclair Compassion Questionnaire (SCQ) and associated healthcare professional measures. This process follows established international guidelines for cross-cultural validation, including forward translation, back-translation, expert panel review, and pilot testing. Cognitive interviewing techniques are used to evaluate comprehension, relevance, and cultural appropriateness among both patients and healthcare professionals. Particular attention is given to semantic equivalence and the contextual meaning of key constructs across languages and professional groups.\n\nPhase 1b (Psychometric Validation):\n\nFollowing adaptation, the instruments are administered to a patient sample recruited from departments of anesthesia, surgery, and intensive care. Data collected in this phase are used to assess the psychometric properties of the translated instruments, including internal consistency, construct validity, factor structure, and measurement invariance. Statistical analyses include confirmatory factor analysis and reliability testing. The aim of this phase is to ensure that the instruments demonstrate robust measurement properties within the Danish healthcare context.\n\nPhase 2 (Observational Implementation Study):\n\nIn the second phase, the validated instruments are implemented across four hospital departments, including medical, nephrology, orthopedic surgery, and emergency care. Data are collected from both patients and healthcare professionals to allow for multi-perspective analysis. In addition to questionnaire data, contextual variables such as demographic characteristics, professional background, and organizational factors are recorded. Administrative data, including sick leave and workforce indicators, are incorporated where available.\n\nThis phase employs a cross-sectional observational design with embedded comparative analyses across departments and professional groups. Multilevel modeling approaches are used to account for clustering within departments and to explore variation at individual and organizational levels. The design enables identification of patterns and differences across settings without introducing experimental manipulation.\n\nPhase 3 (Contextualized Implementation and Development):\n\nThe third phase involves the application of findings from earlier phases to inform targeted implementation strategies. Rather than introducing a predefined intervention, this phase adopts an adaptive approach in which context-specific initiatives are selected or developed based on identified needs. This may include integration of existing training programs, workflow adjustments, or development of new tools. The implementation process is supported by interdisciplinary collaboration, including expertise in clinical practice, education, and organizational development.\n\nData Collection and Management:\n\nData are collected using secure electronic platforms compliant with Danish data protection regulations. All participant data are handled in accordance with GDPR requirements. Identifiable data are stored separately from research data, and access is restricted to authorized personnel. Data quality assurance procedures include validation checks and standardized data entry protocols.\n\nParticipant Involvement:\n\nPatients are recruited during their contact with hospital departments and provide self-reported data through questionnaires. Healthcare professionals participate by completing self-assessment measures. Participation is voluntary, and no experimental interventions are administered.\n\nStatistical Considerations:\n\nThe study uses both descriptive and inferential statistical methods. Psychometric analyses are conducted in Phase 1b, while Phase 2 includes regression analyses and multilevel modeling to examine associations between variables. Missing data are handled using appropriate statistical techniques, such as multiple imputation where relevant.\n\nEthical Considerations:\n\nThe study adheres to ethical guidelines for clinical research involving human participants. Informed consent is obtained from all participants. Participation does not influence clinical care or employment conditions. The study design minimizes participant burden by integrating data collection into existing clinical workflows where possible.",[125,126,127,128,129],"Burnout","Compassion Ability","Compassion Competence","Compassionate Care","Investigate Compassionate Care and Burnout in Healthcare",[131,132,133,134,135,136],"Sinclair Compassion Questionnaire (SCQ)","Validation","Compassion ability for healthcare providers","Compassion competence for healthcare providers","Compassionate care for patients","burnout in healthcare providers","2026-05-12",{"date":139,"type":45},"2026-05-14",{"date":141,"type":45},"2026-02-16",{"date":143,"type":21},"2027-12-31",{"name":51,"class":52},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":153,"enrollmentInfo":154,"targetDuration":156,"studyType":95,"phases":4,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":53},"100630893","capture-hfpef-national-study-of-identification-and-phenotyping-of-heart-failure-with-preserved-ejection-fraction-100630893","NCT07493590","CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction","CAPTURE-HFpEF (Cardiovascular Assessment and Phenotyping for Timely Understanding and Recognition of Evolving Heart Failure With Preserved Ejection Fraction)","CAPTURE-HFpEF","Inclusion Criteria:\n\n* Patients \\>60 years with ≥1 risk factor, OR\n* Patients \\>50 years with ≥2 risk factors\n* Hypertension\n* Type 1 or 2 diabetes\n* Chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²)\n* Previous cardiotoxic drug exposure\n* atrial fibrillation\n* Ischemic heart disease\n* Previous heart valve surgery\u002Fintervention\n* Body mass index \\>30 kg\u002Fm² (self-reported)\n* Use of ≥40 mg furosemide\n* Obstructive sleep apnea\n* Non-alcoholic fatty liver disease\n\nExclusion Criteria:\n\n* Cancer \\\u003C1 year\n* Dialysis\n* COPD and O2\n* Nursing home\n* Age \\>90 years\n* Dementia\n* Known dilated cardiomyopathy\n* Prior organ-transplantation\n* Amyloidosis","90 Years",{"count":155,"type":21},30000,"10 Years","The goal of this observational study is to improve early detection, characterization, and understanding of heart failure with preserved ejection fraction (HFpEF) in adults at risk of or diagnosed with HFpEF, including men and women across Danish regions.\n\nThe main questions to answer are:\n\nCan systematic cardiovascular screening and deep phenotyping improve early identification and classification of HFpEF?\n\nWhich clinical, imaging, biomarker, and metabolic characteristics define subtypes (phenotypes) of HFpEF and predict disease progression and outcomes?\n\nResearchers will compare participants with HFpEF, participants at risk of HFpEF, and relevant control groups to see if differences in biomarkers, imaging findings, and clinical characteristics can identify early disease stages and distinct HFpEF phenotypes.\n\nParticipants identified with HFpEF will:\n\n* Undergo detailed cardiovascular examinations (e.g., echocardiography, CT and other imaging examinations, RHC, CPET)\n* Provide blood and tissue samples for biomarker and metabolic analyses\n* Complete clinical assessments and questionnaires\n* Have relevant health data collected from national health registries\n* Attend follow-up assessments to monitor disease progression",[159],"Heart Failure With Preserved Ejection Fraction (HFPEF)",[161,162,163,164,165],"Heart failure","Heart Failure with Preserved Ejection Fraction (HFpEF)","Cardiovascular Mortality","Cardiovascular Disease","Chronic Heart Failure","NOT_YET_RECRUITING","2026-03-23",{"date":169,"type":45},"2026-03-25",{"date":171,"type":21},"2026-04-01",{"date":173,"type":21},"2035-04-01",{"name":51,"class":52},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":53},"100525995","phase-2-withdrawal-of-treatment-for-heart-failure-patients-with-recovery-from-tachycardia-induced-cardiomyopathy-100525995","NCT06128980","Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy","Withdrawal of Pharmacological Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy - WEAN-HF","WEAN-HF","Inclusion Criteria:\n\nPatients with new onset heart failure (ambulatory or hospital) with reduced ejection fraction (LVEF≤40% assessed by echocardiography) and NYHA ≥2 and atrial fibrillation or atrial flutter with ventricular rate ≥110 bpm (ECG monitoring, hospital telemetry or Holter monitoring) that following GDMT - while AF is terminated (e.g. ablation or conversion) or controlled (HR\\\u003C110 on resting ECG) - experience LVEF remission (LVEF ≥50%), normalization of indexed LV volume, and normal ECG (no bundle branch block, ST segment deviations or T-wave inversion) and NT-proBNP \\\u003C250 pg\u002Fml.\n\nExclusion Criteria:\n\n* 18 years or older and able to consent\n* Former ablation procedures and inability to tolerate antiarrhythmic drugs\n* Pregnancy\n* Congenital heart disease (congenital defects with no hemodyamic effects are not excluded)\n* Previously genotyped positive for genes known to cause cardiomyopathy\n* Probable hypertrophic, restrictive or non-compaction cardiomyopathy\n* Moderate\u002Fsevere valvular disease\n* Suspicion of or known cardiac amyloidosis, sarcoidosis, or other storage\u002Finflammatory disease\n* More than 10% PVCs or documented sustained ventricular arrhythmias\n* History of persistent or permanent AF with ventricular rates \\>110 before incident HF despite best standard of care\n* eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n* Acute myocardial infarction at index\n* Probable medication-, alcohol- or illicit drug use induced AF and\u002For HF\n* Systolic blood pressure \\>160 mmHg (at multiple measurements) at index or history of uncontrollable hypertension\n* Myocarditis\n* Cardiogenic shock at index\n* Aborted sudden cardiac death\n* Pacing-induced cardiomyopathy\n* 1.st degree relative with DCM",{"count":184,"type":21},348,[186,187],"PHASE2","PHASE3","New onset heart failure (HF) is observed in up to 25% of patients with incident atrial fibrillation or flutter (AF). Current guidelines suggest that both conditions (AF \\& HF) be addressed with guideline directed medical therapy (GDMT) for HF and rate or rhythm control of AF. Hence, patients with both conditions are subjected to extensive polypharmacy with possible prognostic benefits, but also possible side effects, such as decreased renal function, dizziness, tiredness and hypotension, as well as the financial burden on both the individual patients and society, in addition to the stigma of having a HF diagnosis.\n\nGuidelines do not inform how to manage long-term patients with HF, who following control of the incident tachycardia (e.g. AF), show full recovery from their HF condition.\n\nThis investigator-initiated, open-label, randomized, non-inferiority trial will test whether incremental weaning of GDMT in patients following full cardiac recovery and AF control is non-inferior compared to continuous GDMT with respect to the primary endpoint of freedom from heart failure deterioration. Furthermore, this study seeks to extensively phenotype these patients (genetic testing, advanced imaging, biomarkers etc.) in order to establish whether certain phenotypes are at lesser or greater risk of deterioration once remission is established. This novel approach of a personalized treatment regimen depending on e.g. genetic profiling could lead to an aggressive treatment in patients at high risk of deterioration and conversely spare patients with a negligible risk, a life-long intensive treatment regimen.\n\nAll HF clinics located in Zealand, Denmark, with a catchment area of \\>2 million citizens, have agreed to participate in the WEAN-HF trial. A total of 348 patients will be randomized. Patients are followed up the 1st year after randomization with clinical examination, biomarkers and echocardiography, and are subsequently followed via Danish nationwide registries for 10 years.",[190,191],"Heart Failure With Reduced Ejection Fraction","Heart Rhythm Disorder","2026-02-20",{"date":194,"type":45},"2026-02-23",{"date":196,"type":45},"2025-01-09",{"date":198,"type":21},"2032-01",{"name":51,"class":52},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":215,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":53},"100617695","the-effect-of-a-digital-mediyoga-program-on-quality-of-life-blood-pressure-and-heart-rate-among-patients-with-atrial-fibrillation-100617695","NCT07321964","The Effect of a Digital MediYoga Program on Quality of Life, Blood Pressure and Heart Rate Among Patients With Atrial Fibrillation","The Effect of MediYoga on Quality of Life, Blood Pressure and Heart Rate Among Patients With Atrial Fibrillation: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18 and above\n* Diagnosed with paroxysmal atrial fibrillation\n* EHRA score at 2 or more\n* Owner of a smartphone or tablet\n* Speaking and reading Danish\n* No comorbidity that restricts them from participating in the intervention\n\nExclusion Criteria:\n\n* Elevated TSH Hormone\n* Participated in mindfulness or yoga exercise regularly at any point during the last two years.",{"count":208,"type":21},456,[24],"Atrial fibrillation (AF) is the most common cardiac arrythmia, associated with increased risk of stroke, heart failure, reduced quality of life (QoL), and psychological distress. This randomized controlled trial investigates the effect of MediYoga - a program incorporating deep breathing, low-intensity yoga, and meditation- on disease-specific QoL, blood pressure, and heart rate in 456 patients with paroxysmal AF. With a strong focus on sustainability, the study is fully digital: participants are recruited online, and the 12-week intervention is delivered through an application to smartphone. Additionally, the participants receive online support via Teams. Data will be collected at baseline, 3, 6, and 12 months. The primary outcome is disease specific QoL; secondary outcomes include blood pressure, heart rate, generic QoL, and psychological wellbeing.\n\nQualitative interviews will explore patients' experiences with the intervention.",[67,212,213,214],"Atrial Fibrillation (Paroxysmal)","Quality of Life","Mental Health",[216,217,218,213,219],"Digital Health Intervention","Atrial Fibrillation","Yoga","Nursing","2026-01-05",{"date":222,"type":45},"2026-01-07",{"date":224,"type":45},"2025-09-01",{"date":226,"type":21},"2028-09-01",{"name":51,"class":52},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":236,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":53},"100570393","implementation-of-nutritional-efforts-on-discharged-older-patients-100570393","NCT06706661","Implementation of Nutritional Efforts on Discharged Older Patients","Implementation of Nutritional Treatment to Older Patients Discharged With the Liaison Team","KMH2","Inclusion Criteria:\n\nPrescription of the Liaison team At nutritional risk according to NRS2002 Age 50+ Can read, hear and understand Danish or English Cognitive able to participate in the study, based on whether they are informed in time, place and own data\n\nExclusion Criteria:\n\nReceives enteral or parenteral nutrition Following a special diet including texture modified food and drinks Short life expectancy Not deemed eligible by the project staff","50 Years",{"count":238,"type":21},2000,[24],"The aim of the study is to implement a nutritional treatment when discharging older patients at risk of malnutrition.\n\nData collected in the study will include an assessment of whether a combination of nutritional treatment and a liaison team reduces the risk of readmissions and mortality, improves nutritional status, physical function and quality of life",[242],"Malnutrition",[244,245,246,247,75,248,249,250,251],"food","dietician","malnutrition","nutrition risk","muscle strength","readmissions","mortality","multimodal","2025-11-27",{"date":254,"type":45},"2025-12-04",{"date":256,"type":45},"2025-01-06",{"date":258,"type":21},"2030-12-31",{"name":51,"class":52},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":270,"conditions":271,"keywords":296,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":53},"100435439","prevalence-and-risk-factors-associated-with-cardiac-comorbidity-in-psoriasis-100435439","NCT04950218","Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA: Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA","Inclusion Criteria:\n\n* Patients 18 years or older with a diagnosis of psoriasis will be invited to participate\n\nExclusion Criteria:\n\n* Patients not able to cooperate to the study\n* Patients unable understand and sign informed consent",{"count":269,"type":21},1000,"In a prospective cohort study (n = 1.000), the investigators aim to investigate the correlation between cardiac biomarkers and advanced echocardiography and determine whether these are prognostic markers of heart disease in patients suffering from psoriasis.",[272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295],"Psoriasis","Cardiovascular Diseases","Cardiovascular Risk Factor","Cardiovascular Pathology","Psoriasis Vulgaris","Psoriatic Nail","Psoriasis Face","Psoriasis Guttate","Psoriasis Gyrata","Psoriasis Diffusa","Psoriasis Palmaris","Psoriasis Annularis","Psoriasis Circinata","Psoriasis Plantaris","Psoriasis Universalis","Psoriasis Geographica","Left Ventricular Dysfunction","Myocardial Infarction","Myocardial Ischemia","Heart Failure","Stroke","Heart Diseases","Heart Failure, Systolic","Heart Failure, Diastolic",[272,297,298,101,299,300],"Echocardiography","Advanced echocardiography","Mortality","Cardiovascular mortality","2025-09-09",{"date":303,"type":45},"2025-09-15",{"date":305,"type":45},"2021-09-01",{"date":307,"type":21},"2034-10-01",{"name":51,"class":52},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":325,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":340},"100598599","effect-of-lymphovenous-anastomosis-on-lower-limb-lymphedema-pragmatic-randomized-controlled-trial-100598599","NCT07073586","Effect of Lymphovenous Anastomosis on Lower Limb Lymphedema: Pragmatic Randomized Controlled Trial","Protocol: Effect of Lymphovenous Anastomosis in the Treatment of Lower Limb Lymphedema - Pragmatic Assessor-Blinded Open-Label Randomized Controlled Trial (PrCT)","Inclusion Criteria:\n\n* LLL International Society of Lymphology (ISL) stage 1-2a (both primary and secondary lymphedema and both unilateral and bilateral)\n* Cancer-free with no recurrence for at least one year\n* Age 18 or above\n* Circumference of the affected leg is at least 1 cm larger than the non-lymphedema leg at the most affected site of lymphedema.\n* Proficiency in Danish language, and ability to provide informed consent.\n* Dermal Backflow Stage 0-4\n\nExclusion Criteria:\n\n* LLL International Society of Lymphology (ISL) stage 2b-3\n* Medical conditions contraindicating surgical intervention or anesthesia, such as severe heart or lung disease\n* Allergy to ICG\n* Ongoing infections or skin diseases in the affected limb\n* Previous surgery or other treatment modalities that could interfere with the study results (previous LVA, liposuction or similar).\n* Dermal Backflow Stage 5\n* Active cancer\n* Heart or kidney conditions that can cause leg swelling\n* A BMI above 28 kg\u002Fm²\n* Current smoker\n* Any foreign objects in the lower extremities (e.g., metal implants, prostheses)\n* Venous insufficiency Unilateral weakness in the lower extremity (e.g., after a stroke)\n* Known iodine allergy (contraindication for ICG injection)\n* Leg length discrepancy (anisomelia) \\> 1.5 cm",{"count":317,"type":21},66,[24],"This multicentre pragmatic randomised controlled trial evaluates lymphovenous anastomosis (LVA) for lower-limb lymphedema (LLL) in Denmark. Adults with unilateral or bilateral International Society of Lymphology (ISL) stage 1-2a LLL who have completed protocol-defined Complete Decongestive Therapy (CDT) are randomised 1:1 to\n\nIntervention arm - LVA surgery plus ongoing compression care\n\nControl arm - Compression care only\n\nRecruitment takes place at the Departments of Plastic Surgery, Herlev-Gentofte Hospital and Odense University Hospital. Outcomes are assessed by independent blinded staff at baseline, 6, 12 and 24 months. A biopsy substudy in ten LVA patients explores inflammatory and fibrotic changes. Primary endpoint is change in L-Dex ratio at 12 months. Secondary endpoints include limb volume, infection rate, lymphoscintigraphy findings, patient-reported outcomes, compression-garment use and anastomosis patency.\n\nThe trial follows Good Clinical Practice and General Data Protection Regulation (GDPR). Patients are covered by the Danish public patient-compensation scheme. Results will be published regardless of outcome, and control participants may opt for LVA after the 12-month visit.",[321,322,323,324],"Lymphedema","Lymphoedema","Lymphoedema of Leg","Lymphedema of Leg",[326,327,328,329,39,330,331],"Lymphovenous Anastomosis","LVA","Lower Limb Lymphedema","Leg Lymphedema","CDT","Compression Therapy","2025-07-29",{"date":334,"type":45},"2025-07-31",{"date":336,"type":45},"2025-05-09",{"date":338,"type":21},"2029-08",{"name":51,"class":52},2,{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":92,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":340},"100560138","home-based-cardiac-rehabilitation-for-people-living-with-heart-failure-and-their-caregivers--the-dkreach-hf-pilot-study-100560138","NCT06573242","Home-based Cardiac Rehabilitation for People Living With Heart Failure and Their Caregivers- The DK:REACH-HF Pilot Study","Home-based Cardiac Rehabilitation for People Living With Heart Failure and Their Caregivers- The DK: REACH-HF Pilot Study","Inclusion Criteria:\n\n* Aged \\> 18 years\n* Confirmed diagnosis of Heart Failure (HF) with reduced Ejection Fraction (HFrEF) (Ejection Fraction (EF) \\\u003C45%)\n* No worsening of HF symptoms within past 2 weeks resulting in hospitalization (to ensure stable patients)\n* Are deemed suitable for participating in Cardiac Rehabilitation (CR) by the outpatient HF clinic\n\nExclusion Criteria:\n\n* Have undertaken CR within the past 12 months\n* Are unwilling\u002Funable to travel to a rehabilitation center in the municipality or at the hospital\n* Are unable to understand the study information and\u002For corporate on giving informed consent",{"count":349,"type":21},75,[24],"Background: Participation in cardiac rehabilitation (CR) is a strong recommendation of clinical guidelines for the management of heart failure (HF) because it is demonstrated to be a clinically effective and cost-effective intervention. Despite this, Danish data shows the uptake of CR is suboptimal (51%). A major barrier is that the traditional mode of CR provision is centre based. Travelling (time and cost), dislike of group exercise, and inconvenient timings are some key problems to participation. A potential solution is use of home-based programmes as an alternative to traditional CR.\n\nA novel home-based programme for patients with HF and their caregivers (REACH-HF), developed in the United Kingdom has achieved improvements in quality of life and proven to be cost effective. The REACH-HF program is translated and adapted into a Danish context (DK: REACH-HF) and is now ready to be tested in a Danish setting.\n\nThe aim of this project is to improve the access and uptake of CR among HF patients in Denmark, particularly in subgroups of patients who currently do not benefit from center-based CR.",[291],[354],"rehabilitation","2025-05-15",{"date":357,"type":45},"2025-05-20",{"date":359,"type":45},"2024-08-08",{"date":361,"type":21},"2026-07-01",{"name":51,"class":52},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":374,"conditions":375,"keywords":382,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":53},"100573386","prehabilitation-prior-to-surgery-for-kidney-tumors-100573386","NCT06745609","Prehabilitation Prior to Surgery for Kidney Tumors","Prehabilitation Prior to Surgery for Kidney Tumors: A Randomized Controlled Research Study (Pre-KiT)","Pre-KiT","Inclusion Criteria:\n\n* 65 years or older\n* cT1 kidney tumor, scheduled for either partial or radical nephrectomy.\n* Clinical Frailty Scale 3-6\n\nExclusion Criteria:\n\n* It is determined by an attending physician, or at a multi-disciplinary team-conference, that a 2-4 week postponement of surgery will not be beneficial for the participant.\n* Participant does not understand Danish og English",{"count":372,"type":21},60,[24],"The goal of this clinical trial is to examine if one month of general health optimization before surgery for kidney tumors can help participants recover more quickly from surgery.\n\nThe optimization process is called prehabiliation, and will last one month. It consists of\n\n1. A comprehensive health assessment\n2. Assisted smoking cessation\n3. A home exercise program.\n\nThe investigators will compare an intervention group receiving one month of prehabilitation with a control group receiving the standard of care.\n\nSome of the main questions the investigators want to answer are\n\n* Are participants in the intervention group more satisfied with their quality of recovery after surgery?\n* Do participants in the intervention group maintain more of their physical abilites compared to the control group?",[376,377,378,379,380,381],"Renal Cancer","Renal Cell Cancer","Kidney Cancers","Stage I Renal Cell Cancer","Prehabilitation","Elderly (People Aged 65 or More)",[380,383,384,385,386,387,388,389],"Quality of life","Kidney tumor","Renal cell tumor","Renal cell cancer","Kidney cancer","Quality of recovery","Elderly","2025-01-22",{"date":392,"type":45},"2025-01-24",{"date":394,"type":45},"2025-01-21",{"date":396,"type":21},"2032-03",{"name":51,"class":52},{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":412,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":53},"100558645","the-effect-of-mediyoga-on-sleep-quality-blood-pressure-and-quality-of-life-in-older-adults-with-hypertension-100558645","NCT06553820","The Effect of MediYoga on Sleep Quality, Blood Pressure, and Quality of Life in Older Adults with Hypertension:","The Effect of MediYoga on Quality of Sleep, Blood Pressure and Quality of Life Among Older People: a Randomized Controlled Study","Inclusion Criteria:\n\n* Older people ≥65 years\n* Diagnosed with hypertension.\n* Speaking and reading Danish.\n* Being able to consent.\n* No comorbidity that restricts them from participating in the intervention.\n* Being the owner or user of a smartphone or tablet.\n\nExclusion Criteria:\n\n* Starting an antihypertension medication during the intervention\n* Antihypertension medication is changed (more than 10% increase or reduction in an already used drug or a switch to another drug) during the intervention, which includes diuretics, ACE inhibitors, Calcium-blockers, or Angiotensin-2-blockers.\n* Participated in mindfulness or yoga exercise regularly at any point during the last two years.\n* Patients who have diagnosed sleep disorders for example sleep apnea or narcolepsy.\n* Taking sleep medication regularly.",{"count":406,"type":21},180,[24],"The goal of this Randomized Controlled Trial is to test if an intervention consisting of Yoga can increase quality of sleep and health related quality of life and decrease BP. Secondary to explore and describe the implementation of a yoga intervention and the participants' experiences and perspectives on the intervention in a process evaluation.\n\nThe main question it aims to contribute knowledge about intervention of Yoga in a home environment for individuals with hypertension aged 65 years or older. Participants will (if they got selected into one of the two interventions groups), participate in Yoga exercises delivered by an app for 2 times a week for 10 weeks. Researchers will compare the intervention groups with the control group to see if Medi yoga has an effect in older people with hypertension.",[410,213,411,214],"Hypertension","Quality of Sleep",[413,410,414,383],"MediYoga","Mindfulness","2024-11-11",{"date":417,"type":45},"2024-11-13",{"date":419,"type":45},"2024-11-04",{"date":421,"type":21},"2026-07",{"name":51,"class":52},{"id":424,"slug":425,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":22,"phases":432,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":446},"100565445","phase-4-a-pragmatic-trial-comparing-empagliflozin-and-dapagliflozin-through-cluster-randomization-embedded-in-the-electronic-health-record-100565445","NCT06642272","A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record","APPLE TREE","Inclusion Criteria:\n\n* Adults aged 18 years or more\n\nExclusion Criteria:\n\n* Incapabability of giving informed consent\n* Withdrawal of informed consent",{"count":431,"type":21},17200,[433],"PHASE4","The aim of this clinical trial is investigate the comparative effectiveness of empagliflozin and dapagliflozin for the treatment of diabetes, chronic kidney disease, and heart failure.\n\nPatients who are prescribed either empagliflozin or dapagliflozin, as part of daily clinical practice at the participating sites, will be included in the study. Treatment will be randomized automatically through the electronic health record software in clusters defined by time of day.\n\nhttps:\u002F\u002Fwww.appletreestudy.com",[436,291,437],"Diabetes Mellitus, Type 2","Chronic Kidney Diseases","2024-11-01",{"date":440,"type":45},"2024-11-05",{"date":442,"type":45},"2024-10-10",{"date":444,"type":21},"2028-12-31",{"name":51,"class":52},12,{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":16,"minAge":236,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":22,"phases":455,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":53},"100473663","migration-and-functional-outcome-of-delta-xtend-reverse-shoulder-lateralized-glenosphere-line-extension-system-100473663","NCT05447819","Migration and Functional Outcome of DELTA Xtend Reverse Shoulder Lateralized Glenosphere Line Extension System","Inclusion Criteria:\n\n1. Rotator cuff arthropathy defined as degeneration of the glenohumeral joint and wear or tear of at least one rotator cuff tendon\n2. Degeneration of the glenohumeral joint with intact rotator cuff function but severe posterior wear of the glenoid (\\>20 degrees posterior wear)\n3. Insufficient effect of non-surgical treatment with symptoms severe enough to justify shoulder arthroplasty.\n4. ASA (American Society of Anesthesiology) score 1-3, physically fit for surgery and rehabilitation\n\nExclusion Criteria:\n\n1. Below 50 years of age\n2. Cognitive or linguistic impairment\n3. Insufficient glenoid bone-stock\n4. Previous fracture in the upper extremities\n5. Patients with autoimmune mediated inflammatory arthritis\n6. Glenoid border medial to the medial border of the coracoid on a true AP radiograph",{"count":454,"type":21},122,[24],"This is a randomized controlled trial comparing the DELTA Xtend Reverse Shoulder System Lateralized Glenosphere Line Extension (intervention group) with the standard DELTA Xtend Reverse Shoulder System (control group). All Danish citizens with rotator cuff arthropathy or degeneration of the glenohumeral joint with severe posterior wear indicating a reverse total shoulder arthroplasty referred to the orthopedic department at Herlev and Gentofte Hospital, Copenhagen University Hospital will be considered for participation in the trial. The following exclude from participation in the study: Below 50 years of age; Cognitive or linguistic impairment; insufficient glenoid bone stock; previous fracture in the upper extremities; autoimmune mediated inflammatory arthritis.A total of 122 patients will be included of which 56 will be part of the roentgen radiostereometric analysis. This will allow a maximum of 20% drop out. The primary outcome is magnitude and pattern of migration of the glenoid component and functional outcome by Western Ontario Osteoarthritis of the Shoulder Index (WOOS score). The secondary outcomes are position of arthroplasty, loosening, inferior scapular notching, patient-reported outcomes, functional outcome, readmission, complications, revisions, changes in bone mineral density of the proximal humerus assessed by duel energy x-ray absorptiometry and economy (cost utility analysis). The patients are examined before the operation and 1 week and 3, 6, 12 and 24 months after the operation.",[458],"Rotator Cuff Arthropathy or Degeneration of the Glenohumeral Joint with Severe Posterior Wear","2024-10-01",{"date":461,"type":45},"2024-10-02",{"date":463,"type":45},"2022-08-01",{"date":465,"type":21},"2027-07-31",{"name":51,"class":52},{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":474,"minAge":17,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":22,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":53},"100531529","penile-vibratory-stimulation-in-the-prevention-of-sexual-dysfunction-and-urinary-incontinence-after-radical-prostatectomy-100531529","NCT06200987","Penile Vibratory Stimulation in the Prevention of Sexual Dysfunction and Urinary Incontinence After Radical Prostatectomy","Planned Penile Vibratory Stimulation in the Prevention of Sexual Dysfunction and Urinary Incontinence After Radical Prostatectomy: a Randomized Controlled Study","Inclusion Criteria:\n\n* Men who are undergoing nerve-sparing radical prostatectomy\n* Pre operative erectile function of IIEF-EF \\> 25\n* Sexually active . Continent before surgery defined as a score of 0 on the ICIQ-SF questionnaire\n\nExclusion Criteria:\n\n* Urinary incontinent before surgery\n* Comorbidity that prevents the patient from taking PDE5-inhibitors\n* Disease in the penis or in the penile skin (Peyronies, phimosis)\n* Problems using the vibrator ie impaired function of the hands","MALE",{"count":476,"type":21},100,[24],"To investigate if post-operative penile vibration stimulation kan be used to reduce or prevent sexual dysfunction and urinary incontinence after radical prostatectomy. This will be done in a randomized, controlled, non-blinded study. Men that undergo nerve preserving surgery for prostate cancer is allocated into an intervention group and a control group. A total of 100 men will be included for a power of 80%. The intervention group will be instructed to use the \"Ferticare 2.0\" vibrator for at least five minutes a day with an amplitude of 1 mm and frequency of 90 Hz (these settings were found in a pilot study) for a total of 9 months.\n\nBoth groups will do the standard pelvic floor training program and both groups will be offered regular phosphodiesterase-5-inhibitor treatment. Before surgery, 3, 6 and 10 months after the patients will have to fill out four different questionnaires regarding sexual and urinary function, including IIEF-EF, EHS, \"neglected side effects\" and ICIQ-SF. (10 months is due to a wash-out period of 1 month after the intervention).\n\nThe collected data will be analysed and the primary goal is to see if there is a significant difference in average spontaneous IIEF-EF score in the two groups 10 months after the surgery.",[480,481],"Erectile Dysfunction Following Radical Prostatectomy","Incontinence","2024-03-08",{"date":484,"type":45},"2024-03-12",{"date":486,"type":45},"2024-02-01",{"date":488,"type":21},"2026-10",{"name":51,"class":52},{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":500,"briefSummary":501,"conditions":502,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":53},"100510614","phase-3-the-colchicine-and-atrial-fibrillation-trial-100510614","NCT05928728","The COLchicine and Atrial FIBrillation Trial","The Colchicine and Atrial Fibrillation Trial","COLFIB","Inclusion Criteria:\n\n1. Living address in the Capital Region of Denmark\n2. Age \\> 18\n3. Diagnosed with paroxysmic\u002Fpersistent AF.\n4. Planned or acute admission for cardioversion of AF with successful outcome.\n5. Female participants should either not be of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing one of the following methods of contraception throughout the study and for 30 days after study completion: Hormonal contraception (oral contraceptives, contraceptive implant, injectable birth control, contraceptive patch, or vaginal ring) or intrauterine device\n6. Participants will have given written, informed consent and are able and willing to comply with the requirements of the study protocol.\n7. Optimal background therapy (in relation to comorbidities and development of heart failure \u002F thromboembolic event) for AF as judged by the investigator.\n\nExclusion Criteria:\n\n1. Colchicine treatment for another cause, e.g. gout\n2. Allergy\u002Fhypersensitivity to colchicine\n3. Uncontrolled hypertension (systolic BP \\>180 mmHg or diastolic BP \\>110 mmHg)\n4. History of malignancy of any organ system excluding a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma, localized prostate cancer and\u002For localized carcinoma in situ of the cervix\n5. Cirrhosis, chronic active hepatitis or other severe hepatic disease\n6. Hemodialysis\n7. Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m2\n8. Systemic treatment with moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors or P-glycoprotein inhibitors (list in Appendix 1)\n9. Permanent AF\n10. Female participants who are pregnant, lactating, or considering becoming pregnant during the study or for 6 months after study completion\n11. Significant drug or alcohol abuse during the last year\n12. Current use of or plans to initiate chronic systemic steroid therapy during the study (topical or inhaled steroids are allowed)\n13. Planned ablation procedure as treatment for AF\n14. If cardiovascular surgery or ablation has been done the past three months prior to inclusion.\n15. Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea\n16. Use of other investigational drugs within 30 days of the time of enrollment\n17. Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his\u002Fher participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.\n18. Suspected AF, confirmed with ECG, at time of inclusion and randomization",{"count":499,"type":21},500,[187],"The purpose of this study to investigate the effects of colchicine on atrial fibrillation recurrence and vascular and cardiac function in patients with atrial fibrillation.",[217],"2024-02-27",{"date":505,"type":45},"2024-02-28",{"date":507,"type":45},"2023-07-03",{"date":509,"type":21},"2028-11-01",{"name":51,"class":52},{"id":512,"slug":513,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":11,"sex":16,"minAge":236,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":22,"phases":520,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":53},"100375030","elbow-hemiarthroplasty-versus-orif-for-distal-humeral-fractures-100375030","NCT04163172","Elbow Hemiarthroplasty Versus ORIF for Distal Humeral Fractures","Elbow Hemiarthroplasty Versus Open Reduction and Internal Fixation for AO\u002FOTA Type C2 and C3 Fractures of Distal Humerus in Patients Aged 50 Years or Above; a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Distal humeral fracture AO\u002FOTA type C2 or C3 confirmed by plain radiographs with 2 perpendicular views and CT scan.\n2. ASA score 1-3 and physically fit for surgery.\n3. Age of 50 years or above.\n\nExclusion Criteria:\n\n1. Patients unable to follow the rehabilitation protocol or answer the Danish questionnaires because of physical or cognitive inabilities as evaluated by the recruiting surgeon.\n2. Significant elbow osteoarthritis as evaluated by the recruiting surgeon based on plain radiographs and CT scan.\n3. Fractures that are older than 6 weeks.\n4. Other associated elbow fractures.\n5. Pathological fractures or relevant elbow pathology.",{"count":519,"type":21},44,[24],"This is a randomized control trial comparing the outcome of ORIF (open reduction and internal fixation) with EHA (elbow hemiarthroplasty) for distal humeral fractures in patients aged 50 years or above.",[523,524,525],"Distal Humerus Fracture","Comminuted Fracture","Intra-Articular Fractures","2023-10-05",{"date":528,"type":45},"2023-10-06",{"date":530,"type":45},"2020-02-01",{"date":532,"type":21},"2032-12-31",{"name":51,"class":52},{"id":535,"slug":536,"hasResults":11,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":22,"phases":543,"briefSummary":544,"conditions":545,"keywords":547,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":53},"100458765","the-melacare-study-a-new-method-for-surveillance-of-melanoma-patients-100458765","NCT05253872","The MELAcare Study: A New Method for Surveillance of Melanoma Patients","The MELAcare Study: a Randomized Controlled Trial of a New Method for Surveillance of Melanoma Patients","Inclusion Criteria:\n\n* Ability to read and understand Danish language\n* Willing and able to give written informed consent\n* Surgical treatment of a clinical stage IA-IIA melanoma within 3 months of inclusion\n\nExclusion Criteria:\n\n* Advanced melanoma, clinical stages IIB, IIC, III, or IV\n* Patients with high risk of a new primary melanoma (dysplastic nevus syndrome, or family history of melanoma)\n* History of melanoma skin cancer prior to the index diagnosis\n* Previous cancer, excluding non-melanoma skin cancer\n* Comorbidity that makes skin self-examination impossible (e.g. physical or mental disabilities, dementia or decreased cognitive function)\n* non-detection of sentinel node in IB and IIA patients",{"count":542,"type":21},378,[24],"The aim of this study is to evaluate a new method of follow-up for patients with low and intermediate risk (stages IA-IIA) melanoma. The investigators will compare different tools for patient support and education combined with clinician supported skin self-examination (SSE) to the current standard-of-care. The hypothesis is that meta-cognitive strategies and clinician supported SSE can lower fear of cancer recurrence (FCR) and promote effective SSE on a regular basis without compromising the detection of new primary melanomas and\u002For metastases.",[546],"Cutaneous Melanoma",[548,549,550,551,552],"cutaneous melanoma","follow-up","nurse-led follow-up","skin self-examination","survivorship","2023-06-23",{"date":555,"type":45},"2023-06-26",{"date":557,"type":45},"2022-03-09",{"date":559,"type":21},"2028-03",{"name":51,"class":52},{"id":562,"slug":563,"hasResults":11,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":4,"eligibilityCriteria":567,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":571,"briefSummary":572,"conditions":573,"keywords":576,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":53},"100483403","arthroscopic-vs-open-bone-grafting-for-scaphoid-delayednonunion-100483403","NCT05574582","Arthroscopic vs. Open Bone Grafting for Scaphoid Delayed\u002FNonunion","Arthroscopic Versus Open Cancellous Bone Grafting for Scaphoid Delayed\u002FNon-union in Adults: Study Protocol for a Randomized Clinical Trial","Inclusion Criteria:\n\n1. Patients aged 18-68 years.\n2. A scaphoid fracture without healing 2-6 months since fracture (delayed union) for cases with either displacement \\>1mm or comminution and failed non-operative treatment.\n3. Scaphoid fracture without healing \\>6 months since fracture (non-union) regardless of displacement, comminution and if previous non-operative treatment has been tried.\n4. ASA 1-3.\n\nExclusion Criteria:\n\n1. Open fractures\n2. Associated trans-scaphoid perilunate dislocation.\n3. Associated fracture in the hand\u002Fupper extremity.\n4. Previous failed surgical treatment for scaphoid delayed\u002Fnon-union.\n5. Stage 2 SNAC or above.\n6. Avascular necrosis of the proximal pole as evaluated with MRI and absence of punctate bleeding intraoperatively.\n7. Patients with gross humpback deformity of HLR \\>0.75 and\u002For DCA \\\u003C70⁰.\n8. Patients unable to understand instructions in Danish, complete the rehabilitation protocol, or answering the questionnaires because of physical or cognitive impairment, as evaluated by the surgeon at the first visit.","68 Years",{"count":570,"type":21},88,[24],"Single site, prospective, observer-blinded randomized controlled trial. Eighty-eight patients aged 18-68 years with scaphoid delayed\u002Fnon-union, will be randomized, 1:1, to either open iliac crest cancellous graft reconstruction or arthroscopic assisted distal radius cancellous chips graft reconstruction. All Danish citizens, referred to the orthopedic department, Copenhagen University Hospital in Gentofte with scaphoid delayed\u002Fnonunion will be offered participation in the trial. Exclusion criteria are: Associated fracture in the hand\u002Fupper extremity, previous failed surgical treatment for scaphoid delayed\u002Fnonunion, stage 2 SNAC or above, avascular necrosis of the proximal pole and gross deformity.\n\nPatients are stratified for smoking habits, proximal pole involvement, and displacement of \\>\u002F\\\u003C2mm. The primary outcome is time to union, measured with repeated CT scans at 2-week intervals from 6 to 16 weeks postoperatively. Secondary outcomes are Quick disabilities of the Arm, Shoulder and Hand (Q-DASH), Visual Analogue scale (VAS), donor site morbidity, union rate, restoration of scaphoid deformity, range of motion, key-pinch, grip strength, EQ5D-5L, patient satisfaction, complications, and revision surgery. Patients are examined before the operation and 1.5, 3, 6, 12 and 24 month after the operation. Online follow-up 5 and 10 years after surgery are performed.",[574,575],"Scaphoid Fracture","Scaphoid Nonunion",[577,578,579,580,581,582],"Scaphoid","Scaphoid nonunion","Cancellous","Graft","Arthroscopic","Timo to union","2023-02-28",{"date":585,"type":45},"2023-03-01",{"date":587,"type":45},"2023-02-15",{"date":589,"type":21},"2028-01-01",{"name":51,"class":52},{"id":592,"slug":593,"hasResults":11,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":95,"phases":4,"briefSummary":600,"conditions":601,"keywords":605,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":616,"locationsCount":53},"100453427","identification-of-new-biomarkers-for-patients-with-cholangiocarcinoma-and-gallbladder-cancer-100453427","NCT05184400","Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer","Identification of New Biomarkers for Patients With Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) - do They Provide New Information Regarding Diagnosis, Treatment Efficacy, Side Effects, or Prognosis?","CHOCA","Inclusion Criteria:\n\n* Histological or cytological diagnosis of BTC\n* Patients referred for treatment of BTC\n* Signed informed consent\n\nExclusion Criteria:\n\n* None",{"count":499,"type":21},"No validated biomarkers exist that can identify patients with biliary tract cancer at an early stage or predict treatment outcomes. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.",[602,603,604],"Biliary Tract Cancer","Cholangiocarcinoma","Gallbladder Cancer",[606,101,607,608,609],"Prospective observational open cohort study","Diagnostics","Prognostics","Prediction of treatment efficacy","2021-12-21",{"date":612,"type":45},"2022-01-11",{"date":614,"type":45},"2015-01-01",{"date":258,"type":21},{"name":51,"class":52},""]